Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivan Babic

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Journal of Translational Medicine|October 20, 2017
A novel small molecule inhibitor of p32 mitochondrial protein overexpressed in gliomaVenkata Yenugonda, Natsuko Nomura, Valentina Kouznetsova, et al.
Human Antibodies|September 19, 2018
Antibody drug conjugates: Progress, pitfalls, and promisesAnubhab Mukherjee, Ariana K Waters, Ivan Babic, et al.
Immunotherapy|June 10, 2017
Cellular immunotherapy of cancer: an overview and future directionsZiqi Tao, Shuang Li, Thomas E Ichim, et al.
Neuro-Oncology Advances|October 28, 2024
A phase 1 dose escalation of pritumumab in patients with refractory or recurrent gliomas or brain metastasesJose Carrillo, Jaya Mini Gill, Charles Redfern, et al.
Human Antibodies|October 18, 2017
Pritumumab, the first therapeutic antibody for glioma patientsIvan Babic, Elmar Nurmemmedov, Venkata M Yenugonda, et al.
Pathology Oncology Research : POR|January 21, 2011
Prognostic significance of carbonic anhydrase IX (CA-IX), endoglin (CD105) and 8-hydroxy-2'-deoxyguanosine (8-OHdG) in breast cancer patientsLidija Beketic-Oreskovic, Petar Ozretic, Zahid N Rabbani, et al.
Scientific Reports|May 17, 2020
Allosteric inhibitor of β-catenin selectively targets oncogenic Wnt signaling in colon cancerAnton Cheltsov, Natsuko Nomura, Venkata M Yenugonda, et al.
Oncotarget|December 22, 2014
Mitochondrial p32 is upregulated in Myc expressing brain cancers and mediates glutamine addictionValentina Fogal, Ivan Babic, Ying Chao, et al.
Biochemical Pharmacology|November 11, 2024
Evaluation of UCP1162, a potent propargyl-linked inhibitor of dihydrofolate reductase with potential application to cancer and autoimmune diseaseDidem Ozcan Tezgin, Shan Kurkcu, Debjani Si, et al.
Plos Genetics|March 6, 2013
A kinome-wide RNAi screen in Drosophila Glia reveals that the RIO kinases mediate cell proliferation and survival through TORC2-Akt signaling in glioblastomaRenee D Read, Tim R Fenton, German G Gomez, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Journal of Translational Medicine|October 20, 2017
A novel small molecule inhibitor of p32 mitochondrial protein overexpressed in gliomaVenkata Yenugonda, Natsuko Nomura, Valentina Kouznetsova, et al.
Human Antibodies|September 19, 2018
Antibody drug conjugates: Progress, pitfalls, and promisesAnubhab Mukherjee, Ariana K Waters, Ivan Babic, et al.
Immunotherapy|June 10, 2017
Cellular immunotherapy of cancer: an overview and future directionsZiqi Tao, Shuang Li, Thomas E Ichim, et al.
Neuro-Oncology Advances|October 28, 2024
A phase 1 dose escalation of pritumumab in patients with refractory or recurrent gliomas or brain metastasesJose Carrillo, Jaya Mini Gill, Charles Redfern, et al.
Human Antibodies|October 18, 2017
Pritumumab, the first therapeutic antibody for glioma patientsIvan Babic, Elmar Nurmemmedov, Venkata M Yenugonda, et al.
Pathology Oncology Research : POR|January 21, 2011
Prognostic significance of carbonic anhydrase IX (CA-IX), endoglin (CD105) and 8-hydroxy-2'-deoxyguanosine (8-OHdG) in breast cancer patientsLidija Beketic-Oreskovic, Petar Ozretic, Zahid N Rabbani, et al.
Scientific Reports|May 17, 2020
Allosteric inhibitor of β-catenin selectively targets oncogenic Wnt signaling in colon cancerAnton Cheltsov, Natsuko Nomura, Venkata M Yenugonda, et al.
Oncotarget|December 22, 2014
Mitochondrial p32 is upregulated in Myc expressing brain cancers and mediates glutamine addictionValentina Fogal, Ivan Babic, Ying Chao, et al.
Biochemical Pharmacology|November 11, 2024
Evaluation of UCP1162, a potent propargyl-linked inhibitor of dihydrofolate reductase with potential application to cancer and autoimmune diseaseDidem Ozcan Tezgin, Shan Kurkcu, Debjani Si, et al.
Plos Genetics|March 6, 2013
A kinome-wide RNAi screen in Drosophila Glia reveals that the RIO kinases mediate cell proliferation and survival through TORC2-Akt signaling in glioblastomaRenee D Read, Tim R Fenton, German G Gomez, et al.
Pageof 4